Welcome to our dedicated page for CPSR news (Ticker: CPSR), a resource for investors and traders seeking the latest updates and insights on CPSR stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect CPSR's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of CPSR's position in the market.
Gelesis' LIGHT-UP clinical trial demonstrated that GS200, an oral superabsorbent hydrogel, effectively aids weight loss in adults with prediabetes or type 2 diabetes. About 60% of participants experienced at least a 5% decrease in body weight, averaging a loss of 11% (about 23 pounds) in just six months. Furthermore, roughly one-third were 'super responders,' losing over 10% of their body weight. The safety profile of GS200 was comparable to the placebo, indicating a promising new avenue in weight management for at-risk populations.
PureTech Health and its Founded Entity, Gelesis Holdings, presented preclinical data at the World of Microbiome Conference in Vienna. The study showed that Gelesis’ proprietary superabsorbent hydrogel, Gel-B, when added to a high-fat diet, positively influenced gut microbiota, enhancing metabolic health indicators such as weight and glucose control. Notably, Gel-B promoted increased growth of Akkermansia muciniphila, beneficial for gut health. The findings suggest Gel-B's therapeutic potential extends beyond mere space occupation in the digestive system.
PureTech Health reported a solid capital base with cash equivalents of $465.7 million as of December 31, 2021. The company has a robust pipeline featuring 27 therapeutics, with 11 clinical trials initiated in 2021. Notably, PureTech's Founded Entities have achieved significant milestones, including FDA marketing approvals for two products. The company is evaluating capital allocation strategies to enhance shareholder value, including potential returns through dividends or buybacks. Its cash runway extends into 2025, supporting ongoing development across its pipeline.
PureTech Health's Founded Entity, Gelesis, has completed a business combination with Capstar Special Purpose Acquisition Corp. Gelesis will begin trading on the New York Stock Exchange under the ticker symbol 'GLS' on January 14, 2022, after securing approximately $105 million in gross proceeds. These funds will primarily support the national launch of Plenity, an FDA-cleared weight management product. With 71 million Americans having gained weight during the pandemic, Gelesis aims to address the rising demand for effective weight management solutions.
Gelesis, known for its FDA-cleared weight management product, Plenity, has successfully completed its business combination with Capstar Special Purpose Acquisition Corp., leading to Gelesis trading under the ticker 'GLS' on the New York Stock Exchange starting January 14, 2022. The transaction raised approximately $105 million, which will primarily support the nationwide launch of Plenity. CEO Yishai Zohar highlighted the growing demand for weight management solutions, particularly after the pandemic, as 71 million Americans gained weight and over half sought to lose it.
Gelesis has appointed
Gelesis, the maker of Plenity®, unveiled an edible billboard in New York City to challenge restrictive dieting norms. Made from seasonal holiday cakes inspired by vegetables, it promotes the message that enjoying favorite foods is compatible with weight loss. The billboard will be active on December 17-18, showcasing free desserts to the public. Gelesis aims to shift the conversation around weight management, emphasizing a balanced approach. Plenity is FDA-cleared and helps users manage weight by increasing satiety with smaller portions. Gelesis plans further launches using proceeds from its merger with Capstar Special Purpose Acquisition Corp. (NYSE: CPSR).
PureTech Health announces the launch of Plenity, an FDA-cleared weight management aid, now available across the United States. The company also appointed Joy Bauer as Chief Nutrition Officer, who will provide nutrition counseling and education for Plenity members. Plenity is designed to help individuals manage weight by feeling satisfied with smaller portions. A subscription costs
Gelesis announces that Plenity®, its FDA-cleared weight management treatment, is now widely available in the United States for adults with a BMI of 25 to 40 kg/m². Joy Bauer, a prominent nutrition authority, has been appointed as Chief Nutrition Officer to enhance education for healthcare professionals and provide support for Plenity members. The subscription for Plenity is priced at $98 for a four-week supply. Gelesis also detailed a business combination with Capstar Special Purpose Acquisition Corp. (CPSR), which aims to support consumer activation around Plenity.
PureTech Health's Founded Entity, Gelesis, announced a $30 million pre-order for its weight management product, Plenity®, from Ro, a leading direct-to-patient healthcare company. The new commercial manufacturing facility is now producing Plenity at scale to meet increasing demand, which has exceeded supply since its beta launch in 2020. Ro anticipates a staggering 1,500% YoY revenue growth for Plenity from December 2020 to December 2021, solidifying weight management as a top request on their platform.
